The FDA has granted orphan drug designation to Autolus Therapeutics' (NASDAQ:AUTL) enriched T-cells genetically modified with a retroviral vector to express two chimeric antigen receptors targeting CD19 and CD22 ((AUTO3)) for the treatment of acute lymphoblastic leukemia (ALL). Source: Seeking Alpha 23/4/2019